Roche Canada and pCPA Complete Negotiations for Perjeta in Neoadjuvant HER2-Positive Early Breast Cancer
核心洞察
Roche Canada (搜索) and the pan-Canadian Pharmaceutical Alliance (pCPA) (搜索) successfully completed negotiations for Perjeta (pertuzumab) (搜索) as a neoadjuvant treatment for HER2 (搜索)-positive early breast cancer, with talks concluding on August 10, 2026.
Perjeta, used in combination with trastuzumab and chemotherapy, delivers a dual blockade of HER signaling pathways and represents the established global standard of care for high-risk HER2 (搜索)-positive early breast cancer.
Canada's Drug Agency (CDA-AMC) (搜索) issued a positive recommendation on October 6, 2025, enabling negotiations to begin in February 2026 and bringing equitable public access closer for Canadian patients.
Hoffmann-La Roche Limited (Roche Canada (搜索)) announced on August 18, 2026, that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) (搜索) for Perjeta (pertuzumab for injection) in combination with trastuzumab and chemotherapy as a neoadjuvant treatment for patients with human epidermal growth factor receptor 2 (HER2 (搜索))-positive, locally advanced, inflammatory or early stage breast cancer (either >2 cm in diameter or node positive). The pCPA negotiates price on behalf of the provinces and territories, making the end of these negotiations on August 10, 2026, a critical step in bringing Perjeta in the neoadjuvant setting closer to public access.
Simon Yunger, Vice President, Value Pricing and Reimbursement at Roche Canada (搜索), said: "We are grateful for the constructive collaboration with our health system partners to finalize this agreement. Alongside this milestone, we applaud clinician and patient advocacy groups, whose tireless commitment keeps patient care at the centre of everything we do. We are now eager to work hand-in-hand with provincial and territorial jurisdictions to ensure every Canadian gains equitable access to this standard of care."
A Long-Awaited Milestone for Canadian Patients
Recognizing the critical importance of this treatment approach, the breast cancer community has long advocated for Canadian patient access. In response, public drug programs brought forward a Non-Sponsored Reimbursement Review. Canada's Drug Agency (CDA-AMC) (搜索) issued a positive recommendation on October 6, 2025, enabling Roche Canada (搜索) and the pCPA to commence negotiations in February 2026—a major breakthrough in advancing access to this indication.
Kimberly Carson, CEO of Breast Cancer Canada, described the development as a milestone: "After years of advocacy, this much-needed agreement means equitable access for Canadian patients with HER2-positive breast cancer (搜索) is within reach. This treatment is standard in most countries and may provide high-risk patients with a better outcome from their diagnosis. Today, Canada is closer to closing a critical treatment gap."
MJ DeCoteau, Founder and Executive Director of Rethink Breast Cancer, added: "Perjeta in the neoadjuvant setting has been available to patients in many countries around the world for years, and now Canadians are one step closer to a treatment with demonstrated efficacy in early breast cancer."
Mechanism of Action and Clinical Rationale
Perjeta is a targeted monoclonal antibody designed to bind to the HER2 (搜索) protein on cancer cells, slowing or stopping their growth. It is specifically engineered to prevent the HER2 receptor from pairing (dimerizing) with other HER receptors (EGFR/HER1, HER3, and HER4), a process critical to tumor growth and survival.
Perjeta and trastuzumab complement each other by binding to different sites on the HER2 (搜索) receptor. When used together with chemotherapy in the neoadjuvant setting, they deliver a comprehensive dual blockade of HER signaling pathways to inhibit tumor progression.
Neoadjuvant treatment is given before surgery and is aimed at reducing tumour size so it is easier to surgically remove. Pathologic complete response (pCR) refers to the absence of invasive cancer in the breast and/or lymph nodes, and achieving pCR following neoadjuvant chemotherapy is a desirable outcome, frequently, as it enables optimization of subsequent treatment decisions.
Disease Burden and Unmet Need
Breast cancer is the most common cancer among Canadian women and the second leading cause of cancer death, with an estimated 32,400 diagnoses and 5,400 deaths expected in 2026. Risk increases substantially with age, predominantly affecting women aged 50 to 69. Most cases in Canada are diagnosed at an early stage when curative-intent treatment can be used to help prevent recurrence.
HER2 (搜索)-positive disease occurs when cancer cells overproduce the HER2 protein (a substance that normally regulates cell growth), causing cells to divide and grow at an accelerated rate. HER2-positive breast cancer (搜索) represents 10–20 per cent of breast cancer cases in Canada and is associated with aggressive disease and high recurrence risk. Treating people with breast cancer early, before the cancer has spread, may improve the chance of preventing the disease from returning.
Cathy Ammendolea, Board Chair of the Canadian Breast Cancer Network (CBCN), emphasized the broader impact of public funding: "A breast cancer diagnosis can significantly alter a person's finances, and this is a bigger burden for those already in a precarious situation before their diagnosis. Public funding of staple treatments for individuals diagnosed with breast cancer provides benefits beyond their health."
Next Steps Toward Public Access
Reaching this important milestone through close collaboration with pCPA has set the stage for the next critical phase. Roche Canada (搜索) is committed to working with provincial and territorial jurisdictions to move quickly through their reimbursement decisions and make Perjeta in the neoadjuvant setting available as soon as possible through public drug plans for patients who need it.